DOCSLIB.ORG

2021 Aetna Florida Five Tier Open Small Group ACA Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Plan for your best health 2020 Aetna Pharmacy Drug Guide Aetna Small Group ACA Formulary: FL Aetna.com Health benefits and health insurance plans are offered, administered and/or underwritten by Aetna Health Inc., Aetna Health Insurance Company of New York, Aetna HealthAssurance Pennsylvania Inc., Aetna Health Insurance Company and/or Aetna Life Insurance Company (Aetna). In Florida, by Aetna Health Inc. and/or Aetna Life Insurance Company. In Utah and Wyoming by Aetna Health of Utah Inc. and Aetna Life Insurance Company. In Maryland, by Aetna Health Inc., 151 Farmington Avenue, Hartford, CT 06156. Each insurer has sole financial responsibility for its own products. 2021 Small Group ACA FL Plan Table of Contents informational................................................................................................................................................................... section....................................................................................................................................144 ANALGESICS - DRUGS TO TREAT PAIN AND INFLAMMATION.................................................14 ANTI - INFECTIVES................................................................................................................................ 26 ANTI-INFECTIVES - DRUGS TO TREAT INFECTIONS....................................................................26 ANTINEOPLASTIC AGENTS - DRUGS TO TREAT CANCER.......................................................... 40 ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES..................................................................... 51 CARDIOVASCULAR - DRUGS TO TREAT HEART AND CIRCULATION CONDITIONS...........51 CENTRAL NERVOUS SYSTEM - DRUGS TO TREAT NERVOUS SYSTEM DISORDERS............66 ENDOCRINE AND METABOLIC - DRUGS TO TREAT DIABETES AND REGULATE HORMONES............................................................................................................................................. 91 GASTROINTESTINAL - DRUGS TO TREAT STOMACH AND INTESTINAL DISORDERS.......117 GENITOURINARY - DRUGS TO TREAT GENITAL AND URINARY TRACT CONDITIONS...127 HEMATOLOGIC - DRUGS TO TREAT BLOOD DISORDERS......................................................... 130 IMMUNOLOGIC AGENTS - DRUGS TO TREAT DISORDERS OF THE IMMUNE SYSTEM.....135 MEDICAL DEVICES.............................................................................................................................. 141 NUTRITIONAL/SUPPLEMENTS - VITAMINS AND SUPPLEMENTS............................................162 OPHTHALMIC - DRUGS TO TREAT EYE CONDITIONS................................................................172 OTHER.....................................................................................................................................................176 PHARMACEUTICAL ADJUVANTS.................................................................................................... 177 RESPIRATORY - DRUGS TO TREAT BREATHING DISORDERS................................................. 177 TOPICAL - DRUGS TO TREAT EAR AND SKIN CONDITIONS.....................................................187 TOC-3 How to use this guide Your guide includes a list of commonly used drugs covered on your pharmacy plan. The amount you pay depends on the drug your doctor prescribes. It’s either a flat fee or a percentage of the prescription’s price after you meet your deductible, if applicable. Preferred generic drugs cost less. Preferred brand drugs will have a higher cost. Your plan includes You’re covered for all types of medicine — some more expensive, and some less. • Brand and generic drugs that are hand-picked for their quality and effectiveness • Preferred generic: the lowest cost • A specialty pharmacy that fills specialty prescriptions • Preferred brand: a slightly higher cost (ones that are injected, infused or taken by mouth) — • Non-preferred brand and generic: a higher cost and provides services that include personal • Preferred Specialty: lower cost for specialty drugs support, helpful resources and training, and free secure home delivery • Non-preferred Specialty: higher cost for non-preferred specialty drugs • A home delivery pharmacy that delivers maintenance drugs to your home or wherever Your pharmacy plan may not have all the coverage levels you choose (for drugs that are taken regularly to listed above so check your plan documents to see how treat conditions like diabetes or asthma) much you will pay. What you can expect to pay For your exact coverage and cost, and to learn more about your plan With your pharmacy plan, the amount you pay depends on the drug your doctor prescribes. It’s either a flat fee or Visit the website that’s on your member ID card. a percentage of the drug’s/medicine’s price. Then log in to your account, where you can: Each drug is grouped as a generic, a brand or a • Find out the coverage* and estimate of cost for specialty drug. The preferred drugs within these specific drugs groups will generally save you money compared • View your deductibles and plan limits to a non-preferred drug. Typically, generic drugs • Order medications are less expensive than brands. • Check your pharmacy order status Specialty prescription drugs typically include higher-cost • Get a member ID card drugs that require special handling, special storage or • View your claims, Explanation of Benefits and more. monitoring. These types of drugs may include, but are not limited to, drugs that are injected, infused, inhaled or taken by mouth. * Check your plan documents for coverage information. Your plan may not cover certain drugs such as infertility, erectile dysfunction, weight loss and smoking cessation. 1 Have more questions about your CVS Caremark Mail Service Pharmacy™ pharmacy benefits? You can have maintenance drugs sent right to your home We’re here to help. There are several ways you can or anywhere else you choose by CVS Caremark Mail learn more about your benefits: Service Pharmacy. These are drugs that are taken regularly for chronic conditions like diabetes or asthma. • Check your Plan Design and Benefits Summary in Depending on your plan, you can get up to a 90-day your enrollment kit. supply of medicine for less cost. It’s fast and convenient, • Call the toll-free number on your member ID card. and standard shipping is always free. • Review our pharmacy frequently asked questions (FAQs) and answers. Just visit the website that’s on Get started right away your member ID card to search for the “Pharmacy FAQ.” You can submit your order using one of these options: Specialty Pharmacy Network 1. Online — Visit your secure member website and An in-network specialty pharmacy can fill your sign in to your account. There you can add or prescriptions for specialty drugs. These are the types remove your prescriptions. of drugs that may be injected, infused or taken by mouth. 2. Phone — Call us toll-free, 24/7 at 1-888-792-3862. They often need special storage and handling. And they If you need the help of a telephone device for the need to be delivered quickly. A nurse or pharmacist may hard of hearing, call 1-877-833-2779. monitor you during your treatment, if needed. With this type of pharmacy, you can get 3. Mail — Get a new prescription from your doctor. Then this medicine sent right to your home. mail it to us with a completed order form. You can find the form on your secure member website. The mailing address is on the form. How to get started with a specialty pharmacy Ordering your prescriptions through our specialty Your doctor can submit your order using one of pharmacy is easy. And we typically offer a 30-day these options: medicine supply. 1. Online — They can submit your prescriptions using • To transfer your prescription, just call us toll-free the e-prescribe services on our provider website. at 1-866-353-1892. 2. Fax — They can fax your prescription to • For a new prescription, your doctor can send it to 1-877-270-3317. Make sure they include your member us in one of four ways: ID number, date of birth and mailing address on the 1. Electronically: Through e-prescribe fax cover sheet. Only a doctor may fax a prescription. 2. Fax: 1-800-323-2445 3. Phone: 1-800-237-2767 If you mail in your own prescription, please send it with a completed Patient Profile Form. To find this form, just visit the website that’s on your member ID card, to search for the “Patient Profile Form.” 2 Frequently asked questions How can I save on prescriptions? What is step therapy? Here are some tips to pay less out of pocket for your Some drugs require step therapy. This means that prescription drugs: you must try one or more prerequisite drug(s) before a step therapy drug is covered. • Ask your doctor to consider prescribing drugs that are on the Pharmacy Drug Guide (formulary). The prerequisite drugs have U.S. Food and Drug • Ask your doctor to consider prescribing generic Administration (FDA) approval and may cost less. They drugs instead of brand-name drugs. treat the same condition as the step therapy drug. • Our home delivery pharmacy may save you money. If you don’t try the appropriate prerequisite drug first, you For more information, visit the website on your may need to pay full cost for the step-therapy drug. member ID card and log in to your account. What are quantity limits? What are generic drugs? Quantity limits help your doctor and pharmacist make Generic drugs are proven to be just as safe and effective sure that you use your drug correctly and safely. We use as brand-name drugs. They contain
Recommended publications
  • Performance of the Insulin-Only Ilet Bionic Pancreas and The

    Performance of the Insulin-Only Ilet Bionic Pancreas and The

    e118 Diabetes Care Volume 44, June 2021 Performance of the Insulin-Only Luz E. Castellanos,1 Courtney A. Balliro,1 Jordan S. Sherwood,1 Rabab Jafri,1 iLet Bionic Pancreas and the Mallory A. Hillard,1 Evelyn Greaux,1 Rajendranath Selagamsetty,2 Hui Zheng,3 Bihormonal iLet Using Firas H. El-Khatib,2 Edward R. Damiano,2,4 and Dasiglucagon in Adults With Type Steven J. Russell1 1 Diabetes in a Home-Use Setting Diabetes Care 2021;44:e118–e120 | https://doi.org/10.2337/dc20-1086 Reductions in blood glucose levels in with insulin lispro (Eli Lilly) or aspart (Table 1). The mean CGM glucose and people with diabetes are often achieved (Novo Nordisk), the bihormonal iLet for time in range (70–180 mg/dL) were 149 at the expense of increased hypoglyce- 7dayswithdasiglucagon(4mg/mL) ±13mg/dLand72±8%,respectively,in mia. A novel approach is to automati- and insulin lispro or aspart, or both, us- the insulin-only period, and 139 ± 11 cally deliver microdose glucagon when ing the same glucose target (110 mg/ mg/dL and 79 ± 9%, respectively, in the automation of insulin delivery alone is dL), in random order. There were no re- bihormonal period. The mean daily car- not sufficient to prevent hypoglycemia. strictions on diet or exercise. The prima- bohydrates consumed to prevent or The approach requires a bihormonal de- ry outcomes were prespecified iLet treat hypoglycemia were 16 ± 13 g and vice and a stable form of glucagon or operational thresholds. The key second- 18 ± 21 g in the insulin-only and bihor- glucagon analog.
  • Saponins, Phytosterols

    Saponins, Phytosterols

    Herbal Pharmacology Saponins, Phytosterols Class Abstract Saponins Mills&Bone p.44-47, p.67, Ginseng monograph (p.635) Rajput, Zahid Iqbal, et al. "Adjuvant effects of saponins on animal immune responses." Journal of Zhejiang University Science B 8.3 (2007): 153-161. Rao, A. V., and M. K. Sung. "Saponins as anticarcinogens." The Journal of nutrition 125.3 Suppl (1995): 717S-724S. Francis, George, et al. "The biological action of saponins in animal systems: a review." British journal of nutrition 88.06 (2002): 587-605. glycyrrhizin dioscin KEY POINTS: Glycosides, steroidal or triterpenoid. Soap-like with sugar moiety being hydrophilic. Act both whole and as aglycones. Interact with hormone (corticosteroid / sex) systems. Increase hepatic cholesterol synthesis and excretion. Interact with immune system. Often toxic by injection Extraction: Water is often excellent. Forms foam. Areas of action: Gut, lymphoid tissue, liver, pituitary, kidney/adrenals. Pharmacokinetics: Micelle formation, various degrees of de-glycosylation in small intestine, though some absorbed whole. Rapid plasma entry (90 min), clearances often longer (8-12h half-lives), perhaps due to enterohepatic recycling. Excreted in bile, some kidney. Representative species: Glycyrrhiza, Panax, Actaea, Saponaria Phytosterols: Mills&Bone Saw Palmetto monograph, pp. 805-810 Demonty, Isabelle, et al. "Continuous dose-response relationship of the LDL-cholesterol– lowering effect of phytosterol intake." The Journal of nutrition 139.2 (2009): 271-284. Phillips, Katherine M., David M. Ruggio, and Mehdi Ashraf-Khorassani. "Phytosterol composition of nuts and seeds commonly consumed in the United States." Journal of agricultural and food chemistry 53.24 (2005): 9436-9445. Ostlund, Richard E., Susan B. Racette, and William F.
  • Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils

    Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils

    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Nutrition & Health Sciences Dissertations & Theses Nutrition and Health Sciences, Department of 5-2010 Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils Mark McKinley Ash University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/nutritiondiss Part of the Dietetics and Clinical Nutrition Commons, and the Molecular, Genetic, and Biochemical Nutrition Commons Ash, Mark McKinley, "Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils" (2010). Nutrition & Health Sciences Dissertations & Theses. 17. https://digitalcommons.unl.edu/nutritiondiss/17 This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition & Health Sciences Dissertations & Theses by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils by Mark McKinley Ash A THESIS Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Master of Science Major: Nutrition Under the Supervision of Professor Timothy P. Carr Lincoln, Nebraska May, 2010 Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils Mark McKinley Ash, M.S. University of Nebraska, 2010 Adviser: Timothy P. Carr Naturally occurring compounds and lifestyle modifications as combination and mono- therapy are increasingly used for dyslipidemia. Specficially, phytosterols and fatty acids have demonstrated an ability to modulate cholesterol and triglyceride metabolism in different fashions.
  • Pearling Barley and Rye to Produce Phytosterol-Rich Fractions Anna-Maija Lampia,*, Robert A

    Pearling Barley and Rye to Produce Phytosterol-Rich Fractions Anna-Maija Lampia,*, Robert A

    Pearling Barley and Rye to Produce Phytosterol-Rich Fractions Anna-Maija Lampia,*, Robert A. Moreaub, Vieno Piironena, and Kevin B. Hicksb aDepartment of Applied Chemistry and Microbiology, University of Helsinki, Finland, and bUSDA, ARS, Eastern Regional Research Center, Wyndmoor, Pennsylvania 19038, ABSTRACT: Because of the positive health effects of phyto- in the kernels and are more concentrated in the outer layers sterols, phytosterol-enriched foods and foods containing than in the starch-rich endosperm (6,7). During the milling of elevated levels of natural phytosterols are being developed. some grains, pearling is a traditional way of gradually remov- Phytosterol contents in cereals are moderate, whereas their lev- ing the hull, pericarp, and other outer layers of the kernels and els in the outer layers of the kernels are higher. The phytosterols germ as pearling fines to produce pearled grains. It is the most in cereals are currently underutilized; thus, there is a need to common technique used to fractionate barley (8). The abra- create or identify processing fractions that are enriched in sion of rye and barley to produce high-starch pearled grains phytosterols. In this study, pearling of hulless barley and rye was investigated as a potential process to make fractions with higher also has been used to improve fuel ethanol production (9,10). levels of phytosterols. The grains were pearled with a labora- There is a need to find new food uses for the pearling fines tory-scale pearler to produce pearling fines and pearled grains. and other possible low-starch by-products remaining after Lipids were extracted by accelerated solvent extraction, and separation of the high-starch pearled grain.
  • PHYTOSTEROLS, PHYTOSTANOLS and THEIR ESTERS Chemical and Technical Assessment

    PHYTOSTEROLS, PHYTOSTANOLS and THEIR ESTERS Chemical and Technical Assessment

    PHYTOSTEROLS, PHYTOSTANOLS AND THEIR ESTERS Chemical and Technical Assessment 1 Prepared by Richard Cantrill, Ph.D., reviewed by Yoko Kawamura, Ph.D., for the 69th JECFA 1. Summary Phytosterols and phytostanols, also referred to as plant sterols and stanols, are common plant and vegetable constituents and are therefore normal constituents of the human diet. They are structurally related to cholesterol, but differ from cholesterol in the structure of the side chain. Commercially, phytosterols are isolated from vegetable oils, such as soybean oil, rapeseed (canola) oil, sunflower oil or corn oil, or from so-called "tall oil", a by-product of the manufacture of wood pulp. These sterols can be hydrogenated to obtain phytostanols. Both phytosterols- and stanols, which are high melting powders, can be esterified with fatty acids of vegetable (oil) origin. The resulting esters are liquid or semi-liquid materials, having comparable chemical and physical properties to edible fats and oils, enabling supplementation of various processed foods with phytosterol- and phytostanol esters. The most common phytosterols and phytostanols are sitosterol (3β-stigmast-5-en-3ol; CAS Number 83- 46-5), sitostanol (3β,5α-stigmastan-3-ol; CAS Number 83-45-4), campesterol (3β-ergost-5-en-3-ol; CAS Number 474-62-4), campestanol (3β,5α-ergostan-3-ol; CAS Number 474-60-2), stigmasterol (3β- stigmasta-5,22-dien-3-ol; CAS Number 83-48-7) and brassicasterol (3β-ergosta-5,22-dien-3-ol; CAS Number 474-67-9). Each commercial source has its own typical composition. Dietary intake of phytosterols ranges from 150-400 mg /day in a typical western diet.
  • Research Journal of Pharmaceutical, Biological and Chemical Sciences

    Research Journal of Pharmaceutical, Biological and Chemical Sciences

    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences Determination of Phytosterols in Beer. Maria Olegovna Rapota1*, and Mikhail Nikolayevich Eliseev2. 1Graduate Student, Plekhanov Russian University of Economics, Stremyanny Lane 36, Moscow, 117997, Russia. 2Candidate of Technical Sciences, Professor, Plekhanov Russian University of Economics, Stremyanny Lane 36, Moscow, 117997, Russia. ABSTRACT Extraction of phytosterols as lipid substances from various plant sources, including corn, is a subject of many foreign publications. However, studies that identify the behavior and influence of phytosterols in the beer making process were not found in the literature. Phytosterols present in cereals as free sterols, fatty acid esters and phenolic acids, glycosides and acylated glycosides. The study showed that phytosterols’ content is entirely dependent on the raw material used. The more a malt part in the grain, the higher is phytosterol content. Phytosterol content accumulates in beer due to the extraction of raw materials from unmalted grain products, malt and hops. Keywords: Phytosterols; raw materials for beer production; beta-sitosterol; campesterol; stigmasterol. *Corresponding author September – October 2016 RJPBCS 7(5) Page No. 328 ISSN: 0975-8585 INTRODUCTION Phytosterols are plant-derived sterols extracted from the non-saponifiable fraction of plant lipids. Over 200 natural phytosterols have been identified, stigmasterol, brassicasterol and beta-sitosterol being the most common ones. Their melting points
  • The Effects of Phytosterols Present in Natural Food Matrices on Cholesterol Metabolism and LDL-Cholesterol: a Controlled Feeding Trial

    The Effects of Phytosterols Present in Natural Food Matrices on Cholesterol Metabolism and LDL-Cholesterol: a Controlled Feeding Trial

    European Journal of Clinical Nutrition (2010) 64, 1481–1487 & 2010 Macmillan Publishers Limited All rights reserved 0954-3007/10 www.nature.com/ejcn ORIGINAL ARTICLE The effects of phytosterols present in natural food matrices on cholesterol metabolism and LDL-cholesterol: a controlled feeding trial X Lin1, SB Racette2,1, M Lefevre3,5, CA Spearie4, M Most3,6,LMa1 and RE Ostlund Jr1 1Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA; 2Program in Physical Therapy, Washington University School of Medicine, St Louis, MO, USA; 3Pennington Biomedical Research Center, Baton Rouge, LA, USA and 4Center for Applied Research Sciences, Washington University School of Medicine, St Louis, MO, USA Background/Objectives: Extrinsic phytosterols supplemented to the diet reduce intestinal cholesterol absorption and plasma low-density lipoprotein (LDL)-cholesterol. However, little is known about their effects on cholesterol metabolism when given in native, unpurified form and in amounts achievable in the diet. The objective of this investigation was to test the hypothesis that intrinsic phytosterols present in unmodified foods alter whole-body cholesterol metabolism. Subjects/Methods: In all, 20 out of 24 subjects completed a randomized, crossover feeding trial wherein all meals were provided by a metabolic kitchen. Each subject consumed two diets for 4 weeks each. The diets differed in phytosterol content (phytosterol-poor diet, 126 mg phytosterols/2000 kcal; phytosterol-abundant diet, 449 mg phytosterols/2000 kcal), but were otherwise matched for nutrient content. Cholesterol absorption and excretion were determined by gas chromatography/mass spectrometry after oral administration of stable isotopic tracers.
  • WO 2014/168736 A9 16 October 2014 (16.10.2014) P O P C T

    WO 2014/168736 A9 16 October 2014 (16.10.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/168736 A9 16 October 2014 (16.10.2014) P O P C T (51) International Patent Classification: (74) Agents: BERMAN, Richard J. et al; ARENT FOX, LLP, A61P 19/04 (2006.01) A61K 31/26 (2006.01) 1717 K Street, N.W., Washington, District of Columbia A61K 31/095 (2006.01) 20036-5342 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 14/029976 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 15 March 2014 (15.03.2014) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 61/794,417 15 March 2013 (15.03.2013) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant: NUTRAMAX LABORATORIES, INC. ZW. [US/US]; 2208 Lakeside Boulevard, Edgewood, Maryland 21040 (US).
  • Study Protocol

    Study Protocol

    CLINICAL TRIAL REPORT ZP4207-17086 (ZEA-DNK-02170) 16.1 TRIAL INFORMATION 16.1.1 PROTOCOL AND PROTOCOL AMENDMENTS This appendix includes Document Date, Version Clinical trial protocol Version 1.0, 08 June 2018 (valid in Slovenia and the USA) Version 3.0, 08 January 2019 (valid in Germany) Section 16.1.1: Protocol and Protocol Amendments Clinical Trial Protocol, final version 1.0 ZP4207-17086 (ZEA-DNK-02170) Clinical Trial Protocol A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children with T1DM treated with insulin Sponsor code: ZP4207-17086 Synteract: ZEA-DNK-02170 EudraCT number: 2018-000892-33 Coordinating investigator: Prof. Dr. med. Thomas Danne Allgemeine Kinderheilkunde Diabetologie, Endokrinologie, Klinische Forschung Diabeteszentrum für Kinder und Jugendliche AUF DER BULT Kinder- und Jugendkrankenhaus Janusz-Korczak-Allee 12 30173 Hannover Germany Sponsor: Zealand Pharma A/S Smedeland 36 2600 Glostrup, Copenhagen Denmark Version: final version 1.0 Date: 08 June 2018 GCP statement This trial will be performed in compliance with Good Clinical Practice, the Declaration of Helsinki (with amendments) and local legal and regulatory requirements. 08 June 2018 CONFIDENTIAL Page 1/55 Zealand Pharma A/S ClinicalTrial Prolocol, final ve¡sion 1.0 zP 42A7 -1 7 A 86 (ZEA-DN K-02 1 L Slgnature¡ and agreoment wlth protocot Tltle: phase A 3, ¡andomized, double-blind, placebo- and aclivg-controlled, parallel-arm trial to assess the efficac¡ safety, and pharmacoítinetics of dasiglucagon rela¡ve to placebo and GlucaGeno when edministered as a rescue thêrapy for sevãre triposivcemia ¡n children w¡th TlDM treated with insulin we, the undersigned, agroe to conduct lhls trlal according to lhe Trlal protocol.
  • A Novel WRKY Transcription Factor Hmowrky40 Associated with Betalain Biosynthesis in Pitaya (Hylocereus Monacanthus) Through Regulating Hmocyp76ad1

    A Novel WRKY Transcription Factor Hmowrky40 Associated with Betalain Biosynthesis in Pitaya (Hylocereus Monacanthus) Through Regulating Hmocyp76ad1

    International Journal of Molecular Sciences Article A Novel WRKY Transcription Factor HmoWRKY40 Associated with Betalain Biosynthesis in Pitaya (Hylocereus monacanthus) through Regulating HmoCYP76AD1 Lulu Zhang †, Canbin Chen †, Fangfang Xie, Qingzhu Hua, Zhike Zhang , Rong Zhang, Jianye Chen , Jietang Zhao , Guibing Hu and Yonghua Qin * State Key Laboratory for Conservation and Utilization of Subtropical Agrobioresources/Guangdong Provincial Key Laboratory of Postharvest Science of Fruits and Vegetables/Key Laboratory of Biology and Genetic Improvement of Horticultural Crops (South China), Ministry of Agriculture and Rural Affairs, College of Horticulture, South China Agricultural University, Guangzhou 510642, Guangdong, China; [email protected] (L.Z.); [email protected] (C.C.); [email protected] (F.X.); [email protected] (Q.H.); [email protected] (Z.Z.); [email protected] (R.Z.); [email protected] (J.C.); [email protected] (J.Z.); [email protected] (G.H.) * Correspondence: [email protected]; Tel.: +86-020-85287296 † These authors contribute equally to this work. Abstract: Betalains are water-soluble nitrogen-containing pigments with multiple bioactivities. Pitaya is the only large-scale commercially grown fruit containing abundant betalains for consumers. How- ever, the upstream regulators in betalain biosynthesis are still not clear. In this study, HmoWRKY40, a novel WRKY transcription factor, was obtained from the transcriptome data of pitaya (Hylo- Citation: Zhang, L.; Chen, C.; Xie, F.; cereus monacanthus). HmoWRKY40 is a member of the Group IIa WRKY family, containing a con- Hua, Q.; Zhang, Z.; Zhang, R.; Chen, served WRKY motif, and it is located in the nucleus. The betalain contents and expression levels of J.; Zhao, J.; Hu, G.; Qin, Y.

  • Fungal Endophytes As Efficient Sources of Plant-Derived Bioactive

    microorganisms Review Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Discovery: Insights, Avenues, and Challenges Archana Singh 1,2, Dheeraj K. Singh 3,* , Ravindra N. Kharwar 2,* , James F. White 4,* and Surendra K. Gond 1,* 1 Department of Botany, MMV, Banaras Hindu University, Varanasi 221005, India; [email protected] 2 Department of Botany, Institute of Science, Banaras Hindu University, Varanasi 221005, India 3 Department of Botany, Harish Chandra Post Graduate College, Varanasi 221001, India 4 Department of Plant Biology, Rutgers University, New Brunswick, NJ 08901, USA * Correspondence: [email protected] (D.K.S.); [email protected] (R.N.K.); [email protected] (J.F.W.); [email protected] (S.K.G.) Abstract: Fungal endophytes are well-established sources of biologically active natural compounds with many producing pharmacologically valuable specific plant-derived products. This review details typical plant-derived medicinal compounds of several classes, including alkaloids, coumarins, flavonoids, glycosides, lignans, phenylpropanoids, quinones, saponins, terpenoids, and xanthones that are produced by endophytic fungi. This review covers the studies carried out since the first report of taxol biosynthesis by endophytic Taxomyces andreanae in 1993 up to mid-2020. The article also highlights the prospects of endophyte-dependent biosynthesis of such plant-derived pharma- cologically active compounds and the bottlenecks in the commercialization of this novel approach Citation: Singh, A.; Singh, D.K.; Kharwar, R.N.; White, J.F.; Gond, S.K. in the area of drug discovery. After recent updates in the field of ‘omics’ and ‘one strain many Fungal Endophytes as Efficient compounds’ (OSMAC) approach, fungal endophytes have emerged as strong unconventional source Sources of Plant-Derived Bioactive of such prized products.
  • Changing Lives with Next Generation Peptide Therapeutics

    Changing Lives with Next Generation Peptide Therapeutics

    Changing lives with next generation peptide therapeutics Zealand Pharma Corporate Presentation May 2019 Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this presentation or any other information transmitted or made available to the viewer or recipient hereof, whether communicated in written or oral form. This presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire Zealand securities, in any jurisdiction, or an inducement to enter into investment activity, nor shall there be any sale of Zealand securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation contains forward-looking statements that reflect management's current views with respect to Zealand's product candidates' development, clinical and regulatory timelines and anticipated results, market opportunity, potential financial performance and other statements of future events or conditions. Although Zealand believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct.